ClinicalTrials.gg
CompletedNCT03924427Updated Nov 2, 2022Results posted

An Investigational Study to Evaluate Experimental Medication BMS-986165 in Japanese Participants With Moderate-to-Severe Psoriasis

A Phase 3 interventional study of BMS-986165 in Psoriasis, sponsored by Bristol-Myers Squibb. Completed at 27 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2022-11-02.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
74
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing deucravacitinib in Psoriasis — 6 open to participants now, 6 under way, 4 of them phase 3. deucravacitinib · Psoriasis.

Enrollment
14th of 26
74 · median 102
Started
2019
with 3 others
Phase 3
9 of 26
4 open now
Registered
9th of 26
by date
Lead sponsor
18 of 26
Bristol-Myers Squibb

Among the 26 studies testing deucravacitinib in Psoriasis, this one is the 14th largest by enrollment, is one of 4 that started in 2019, is one of 9 in phase 3, and was the 9th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

6 of the 26 studies testing deucravacitinib in Psoriasis are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About deucravacitinib

deucravacitinib: first FDA approval 2022 (SOTYKTU), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing deucravacitinib in Psoriasis, or all of them as a file.
02

Study summary

The purpose of this study is to investigate BMS-986165 given to Japanese participants with moderate-to-severe psoriasis.

03

Conditions studied

  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

a. For participants with plaque psoriasis: i. Stable plaque psoriasis for at least 6 months ii. Moderate to severe disease iii. Candidate for phototherapy or systemic therapy b. Additional protocol-specified inclusion criteria apply for subjects with psoriatic arthritis, erythrodermic psoriasis, or generalized pustular psoriasis

Exclusion criteria

Exclusion Criteria:

  1. Guttate, inverse, or drug-induced psoriasis at Screening or Baseline
  2. History of recent infection
  3. Prior exposure to BMS-986165

Other protocol defined inclusion/exclusion criteria could apply

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    BMS-986165

    Given daily

    Drug: BMS-986165

Interventions

06

What researchers measure

Primary outcomes

  1. Static Physician's Global Assessment (sPGA) 0/1 Response as a Number of Participants With a sPGA Score of 0 or 1 at Week 16

    The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scale, and induration. sPGA 0/1 is the response as a number of participants who experience a sPGA score that determines psoriasis severity as clear (0) or almost clear (1) with at least 2-point improvement from baseline at week 16 using the non-responder imputation (NRI) method. The higher sPGA score denotes to more severe disease activity: * Clear (0) * Almost clear (1) * Mild (2) * Moderate (3) * Severe (4)

    Time frame: Week 16

  2. Psoriasis Area and Severity Index (PASI) 75 Response Assessed as a Number of Participants Who Achieve a 75% Improvement From Baseline in the PASI Score at Week 16

    PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the response as a number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value using the non-responder imputation (NRI) method.

    Time frame: Week 16

07

Results

Posted Nov 2, 2022

Participant flow

Participant flow — Overall Study
MilestoneDeucravacitinib 6 mg QD
Started74
Completed68
Not completed6
Withdrew: Adverse event4
Withdrew: Lack of efficacy1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryStatic Physician's Global Assessment (sPGA) 0/1 Response as a Number of Participants With a sPGA Score of 0 or 1 at Week 16

The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scale, and induration. sPGA 0/1 is the response as a number of participants who experience a sPGA score that determines psoriasis severity as clear (0) or almost clear (1) with at least 2-point improvement from baseline at week 16 using the non-responder imputation (NRI) method. The higher sPGA score denotes to more severe disease activity: * Clear (0) * Almost clear (1) * Mild (2) * Moderate (3) * Severe (4)

Time frame:
Week 16
Reported as:
Count of participants · Participants
Static Physician's Global Assessment (sPGA) 0/1 Response as a Number of Participants With a sPGA Score of 0 or 1 at Week 16
ParticipantsPlaque Psoriasis 6 mg QDGeneralized Pustular Psoriasis 6 mg QDErythrodemic Psoriasis 6 mg QD
Static Physician's Global Assessment (sPGA) 0/1 Response as a Number of Participants With a sPGA Score of 0 or 1 at Week 165204
PrimaryPsoriasis Area and Severity Index (PASI) 75 Response Assessed as a Number of Participants Who Achieve a 75% Improvement From Baseline in the PASI Score at Week 16

PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the response as a number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value using the non-responder imputation (NRI) method.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Psoriasis Area and Severity Index (PASI) 75 Response Assessed as a Number of Participants Who Achieve a 75% Improvement From Baseline in the PASI Score at Week 16
ParticipantsPlaque Psoriasis 6 mg QDGeneralized Pustular Psoriasis 6 mg QDErythrodemic Psoriasis 6 mg QD
Psoriasis Area and Severity Index (PASI) 75 Response Assessed as a Number of Participants Who Achieve a 75% Improvement From Baseline in the PASI Score at Week 164823

Adverse events

Collected over Serious Adverse Events and Adverse Events were monitored from first dose to 30 days post last dose (Up to approximately 3 months). Participants were assessed for All Cause Mortality from their date of randomization until study completion (Up to approximately 23 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Deucravacitinib 6 mg QD0/74 (0%)5/74 (6.8%)40/74 (54.1%)
Most frequent serious events
Most frequent serious events
EventDeucravacitinib 6 mg QD
COVID-19Infections and infestations1/74
PneumoniaInfections and infestations1/74
Hodgkin's diseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/74
Normal pressure hydrocephalusNervous system disorders1/74
AsthmaRespiratory, thoracic and mediastinal disorders1/74
Most frequent other events
Most frequent other events
EventDeucravacitinib 6 mg QD
NasopharyngitisInfections and infestations23/74
AcneSkin and subcutaneous tissue disorders7/74
ConstipationGastrointestinal disorders4/74
StomatitisGastrointestinal disorders4/74
PeriodontitisInfections and infestations4/74
Upper respiratory tract infectionInfections and infestations4/74
PsoriasisSkin and subcutaneous tissue disorders4/74

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Deucravacitinib 6 mg QD
Mean48.6 ± 11.72
Sex: Female, Male
Sex: Female, Male(Participants)Deucravacitinib 6 mg QD
Female17
Male57
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Deucravacitinib 6 mg QD
Asian - Japanese73
Asian - Non-Japanese1
08

Study locations

27 sites
  • Local Institution - 0014
    Nagoya, Aichi 467-8602, Japan
  • Local Institution
    Toon-Shi, Ehime 791-0295, Japan
  • Fukuoka University Hospital
    Fukuoka-shi, Fukuoka 814-0180, Japan
  • University of Occupational and Environmental Health, Japan
    Kitakyushu, Fukuoka 807-8555, Japan
  • Sapporo Skin Clinic
    Sapporo, Hokkaido 060-0063, Japan
  • Kobe University Hospital
    Kobe, Hyogo 650-0017, Japan
  • Local Institution
    Morioka, Iwate 0208505, Japan
  • Tokai University Hospital
    Isehara City, Kanagawa 259-1193, Japan
  • National Hospital Organization Yokohama Medical Center
    Yokohama-shi, Kanagawa 2458575, Japan
  • Yokohama City University Hospital
    Yokohama, Kanagawa 236-0004, Japan
  • Kochi Medical School Hospital
    Nakoku, Kochi 783-8505, Japan
  • University Hospital - Kyoto Preferctural University of Medicine
    Kyoto-city, Kyoto 602-8566, Japan
  • Kyoto University Hospital
    Kyoto-City, Kyoto 606-8507, Japan
  • Mie University Hospital
    Tsu, MIE 514-8507, Japan
  • Local Institution - 0004
    Matsumoto, Nagano 3908621, Japan
  • Kurashiki Central Hospital
    Kurashiki, Okayama 7108602, Japan
  • Hamamatsu University Hospital
    Hamamatsu, Shizuoka 431-3192, Japan
  • Jichi Medical University Hospital
    Shimotsuke, Tochigi 329-0498, Japan
  • Nihon University Itabashi Hospital
    Itabashi-ku, Tokyo 173-8610, Japan
  • Teikyo University Hospital
    Itabashi, Tokyo 173-8605, Japan
  • The Jikei University Hospital
    Minato-ku, Tokyo 105-8471, Japan
  • NTT Medical Center Tokyo
    Shinagawa, Tokyo 141-8625, Japan
  • Tokyo Medical University Hospital
    Shinjuku-ku, Tokyo 1600023, Japan
  • Japan Community Health Care Organization Tokyo Yamate Medical Center
    Shinjuku, Tokyo 169-0073, Japan
  • Kumamoto University Hospital
    Kumamoto, 860-8556, Japan
  • Local Institution - 0003
    Osaka, 545-8586, Japan
  • Local Institution - 0012
    Osaka, 550-0006, Japan
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Mar 2021, 23 months.

Results were first posted in Nov 2022, 1 year 7 months after primary completion. A results delay was requested in Mar 2022.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 23 months is above that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2019
First posted
Apr 23, 2019
StartActual
Apr 10, 2019
Primary completionActual
Mar 24, 2021
CompletionActual
Mar 24, 2021
Results delay requested
Mar 21, 2022
Results first posted
Nov 2, 2022
Last update
Nov 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03924427
Responsible party
Sponsor
First posted
Apr 23, 2019
Start date
Apr 10, 2019
Primary completion
Mar 24, 2021
Completion
Mar 24, 2021
Results posted
Nov 2, 2022
Last update
Nov 2, 2022

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deucravacitinib

Start the discussion